About
GISAID (Global Initiative on Sharing All Influenza Data) is a globally recognized platform that provides open access to genomic sequence data of respiratory and other infectious disease pathogens, including influenza viruses, SARS-CoV-2, and mpox virus. Originally established for influenza surveillance, GISAID expanded significantly during the COVID-19 pandemic to become the world's primary repository for SARS-CoV-2 genome sequences, enabling real-time tracking of variant evolution and spread. The platform supports three major databases: EpiCoV (SARS-CoV-2), EpiFlu (influenza), and EpiPox (mpox), each offering curated genomic sequences paired with rich epidemiological metadata. Researchers can analyze viral phylogenetics, monitor emerging mutations, and assess antiviral susceptibility — all through data submitted by laboratories from over 100 countries. GISAID enforces a unique data-sharing model that grants access under agreed terms, protecting the intellectual rights of data contributors while facilitating global scientific collaboration. Its compliance framework includes a dedicated Compliance Board and periodic audits to ensure data is used appropriately. The platform is widely used by virologists, epidemiologists, public health authorities (including WHO and CDC), and bioinformaticians to power dashboards, outbreak reports, and genomic epidemiology research. GISAID also maintains Regional Hubs — such as its Central Africa hub — to strengthen surveillance capacity in low- and middle-income countries. Access is free upon registration and agreement to GISAID's terms of use.
Key Features
- Multi-Pathogen Genomic Databases: Hosts three specialized databases — EpiCoV (SARS-CoV-2), EpiFlu (influenza), and EpiPox (mpox) — providing curated genomic sequences and metadata for global viral surveillance.
- Real-Time Outbreak Monitoring: Enables tracking of viral variant emergence and spread in near real-time, supporting rapid public health response during pandemics and outbreaks.
- Rich Epidemiological Metadata: Each submitted sequence is linked to contextual metadata such as geographic origin, collection date, and host type, enabling detailed phylogeographic analyses.
- Contributor Rights Protection: A formal compliance framework with a Compliance Board and usage audits ensures that data contributors' rights are upheld and that access permissions are enforced appropriately.
- Global Regional Hubs: Regional hubs — including one in Central Africa — extend GISAID's reach and support genomic surveillance capacity in underrepresented regions of the world.
Use Cases
- Tracking the emergence and global spread of SARS-CoV-2 variants (e.g., Delta, Omicron) using phylogenetic analysis of submitted genome sequences.
- Monitoring highly pathogenic avian influenza (HPAI H5N1) outbreaks in animals and human spillover events to inform antiviral treatment decisions.
- Conducting genomic epidemiology research to understand mpox Clade Ib transmission chains across Central and Eastern Africa.
- Powering public health dashboards and variant prevalence visualizations for national and international health agencies.
- Supporting WHO pandemic preparedness efforts by providing harmonized global genomic surveillance data across multiple pathogens.
Pros
- World's Largest Pathogen Sequence Repository: GISAID hosts millions of viral genome sequences contributed by laboratories worldwide, making it the definitive resource for genomic epidemiology.
- Free Access with Registration: All researchers can access GISAID data at no cost by agreeing to the database access terms, lowering barriers to global public health science.
- Trusted by Leading Health Agencies: WHO, CDC, ECDC, and hundreds of public health institutions rely on GISAID data for official variant tracking and pandemic response policy.
- Supports Equity in Global Health: Regional hubs and partnerships in Africa and other regions help ensure low- and middle-income countries can both contribute to and benefit from genomic surveillance.
Cons
- Access Requires Registration and Agreement: Users must register and agree to GISAID's terms of use before accessing data, adding a step compared to fully open repositories like NCBI GenBank.
- Data Use Restrictions: GISAID's data-sharing model places restrictions on downstream use and redistribution, which can complicate integration into some open-science pipelines.
- Not an AI-Native Tool: GISAID is a data repository and surveillance platform, not an AI-powered analytics tool — users must bring their own bioinformatics and analytical infrastructure.
Frequently Asked Questions
What is GISAID and what data does it contain?
GISAID is a global initiative and open-access database that hosts genomic sequence data for respiratory and infectious disease pathogens, including influenza viruses (EpiFlu), SARS-CoV-2 (EpiCoV), and mpox virus (EpiPox), along with associated epidemiological metadata.
Is GISAID free to use?
Yes, access to GISAID is free. Users must register for an account and agree to GISAID's Database Access Agreement before downloading or submitting data.
Who can submit data to GISAID?
Any registered laboratory, researcher, or public health institution can submit viral genome sequences to GISAID. Contributors retain attribution rights and their data usage is protected under GISAID's compliance framework.
How does GISAID protect data contributors?
GISAID enforces strict terms of use through a Compliance Board and periodic audits. Data feeds or supplementary permissions can be revoked if usage diverges from the agreed purposes, while standard access remains available.
What pathogens does GISAID currently cover?
GISAID covers influenza viruses (all types and subtypes), SARS-CoV-2 and related coronaviruses, and mpox virus including Clade Ib and recombinant strains, with additional pathogens added in response to emerging threats.
